
CRVS
Healthcare · Biotechnology · $897.5M market cap
$10.64+0.02 (+0.2%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -3.3% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | -0.21 | -0.22 | -4.8% |
| Aug 6, 2026 | After the close | -0.17 | -0.19 | -11.8% |
| May 7, 2026 | After the close | -0.15 | -0.15 | 0.0% |
| Mar 5, 2026 | Time not confirmed | -0.13 | -0.15 | -18.5% |
| Nov 4, 2025 | After the close | -0.13 | -0.12 | +7.7% |
| Aug 7, 2025 | After the close | -0.13 | -0.10 | +23.1% |
| May 8, 2025 | After the close | -0.12 | -0.14 | -16.7% |
| Mar 17, 2025 | After the close | -0.12 | -0.14 | -19.1% |
| Nov 12, 2024 | After the close | -0.12 | -0.60 | -400.0% |
| Aug 6, 2024 | After the close | -0.11 | -0.07 | +36.4% |
| May 6, 2024 | After the close | -0.13 | -0.12 | +7.7% |
| Mar 19, 2024 | After the close | -0.12 | -0.14 | -16.7% |
| Nov 7, 2023 | After the close | -0.12 |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2…
| -0.12 |
| 0.0% |
| Aug 8, 2023 | After the close | -0.14 | -0.14 | 0.0% |
| May 8, 2023 | After the close | -0.17 | -0.17 | 0.0% |
| Mar 28, 2023 | After the close | -0.23 | -0.21 | +8.7% |
| Nov 3, 2022 | After the close | -0.14 | -0.32 | -128.6% |
| Aug 8, 2022 | After the close | -0.18 | -0.18 | 0.0% |
| May 5, 2022 | After the close | -0.15 | -0.18 | -20.0% |
| Mar 10, 2022 | After the close | -0.19 | -0.20 | -5.3% |
| Nov 1, 2021 | After the close | -0.24 | -0.24 | 0.0% |
| Aug 2, 2021 | After the close | -0.31 | -0.28 | +9.7% |
| Apr 29, 2021 | After the close | -0.31 | -0.34 | -9.7% |
| Mar 25, 2021 | Before the open | -0.32 | -0.33 | -3.1% |
| Oct 29, 2020 | After the close | -0.22 | -0.33 | -50.0% |
| Jul 30, 2020 | After the close | -0.24 | -0.36 | -50.0% |
| Apr 30, 2020 | After the close | -0.40 | -0.44 | -10.0% |
| Mar 5, 2020 | After the close | -0.33 | -0.38 | -15.2% |
| Oct 29, 2019 | After the close | -0.43 | -0.37 | +14.0% |
| Aug 1, 2019 | After the close | -0.44 | -0.44 | 0.0% |
| May 9, 2019 | After the close | -0.48 | -0.40 | +16.7% |
| Mar 7, 2019 | After the close | -0.46 | -0.36 | +21.7% |
| Nov 1, 2018 | After the close | -0.49 | -0.36 | +26.5% |
| Aug 2, 2018 | After the close | -0.61 | -0.40 | +34.4% |
| May 3, 2018 | After the close | -0.77 | -0.63 | +18.2% |
| Mar 1, 2018 | After the close | -0.77 | -0.58 | +24.7% |